GlassScriptPhysician profile
Danielle Erin Jackson
NPI 1699341347
$12,581.59
in general payments reported to CMS, 2019-2025
32 companies · $2,964 in 2025
The $2,964 reported for 2025 was more than what 98% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $125 · 2022: $257 · 2023: $3,626 · 2024: $5,610 · 2025: $2,964.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Education: $26.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,173.53 |
| Education | $26.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,915.74 | 2023-2025 | |
| Gilead Sciences, INC. | $1,581.21 | 2023-2024 | Epclusa, Vemlidy, Livdelzi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,504.08 | 2023-2025 | Xifaxan, Trulance |
| Aimmune Therapeutics, INC. | $969.87 | 2024-2025 | Vowst, Zenpep |
| Ardelyx, INC. | $948.22 | 2023-2025 | Ibsrela |
| Phathom Pharmaceuticals, INC. | $661.32 | 2023-2025 | Voquezna |
| Astrazeneca Pharmaceuticals LP | $616.54 | 2025 | Airsupra, Breztri, Farxiga |
| Janssen Biotech, INC. | $596.66 | 2023-2024 | Stelara, Tremfya, Abiraterone Acetate |
| Pfizer INC. | $409.87 | 2023-2025 | |
| Madrigal Pharmaceuticals | $340.53 | 2024-2025 | Rezdiffra, Resmetirom |
| Lilly USA, LLC | $247.77 | 2022-2025 | Mounjaro |
| Takeda Pharmaceuticals U.S.A., INC. | $225.07 | 2023-2024 | Entyvio |
| Celgene Corporation | $214.21 | 2024 | Zeposia |
| Glaxosmithkline, LLC. | $187.80 | 2023-2025 | Nucala, Trelegy Ellipta |
| Nestle Healthcare Nutrition INC. | $186.13 | 2023 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $162.54 | 2025 | Repatha, Repatha, Otezla |
| Ironwood Pharmaceuticals, INC | $142.84 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $124.99 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $122.08 | 2024 | |
| Genzyme Corporation | $80.41 | 2023-2025 | |
| Intercept Pharmaceuticals, INC. | $62.80 | 2023 | Ocaliva |
| Celltrion USA INC. | $61.91 | 2023-2024 | Vegzelma, Yuflyma |
| Braintree Laboratories, INC. | $35.44 | 2023 | Sutab |
| Sumitomo Pharma America, INC. | $27.91 | 2025 | Gemtesa |
| Bayer Healthcare Pharmaceuticals INC. | $27.09 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $25.11 | 2023 | Dupixent |
| Hologic Sales and Service, LLC | $24.11 | 2025 | Aptima |
| Acella Pharmaceuticals, LLC | $17.76 | 2025 | NP Thyroid 60 |
| Qol Medical, LLC | $16.58 | 2024 | Sucraid |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $16.32 | 2022 | |
| Exact Sciences Corporation | $15.63 | 2025 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.05 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Jackson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.